EACS2023: 898 HBcAb positivity is a risk factor for failure to achieve complete virologic suppression of HIV-RNA after antiretroviral switch to 3TC+DTG V. Malagnino , T. Mulas , E. Teti , Y. Abi Aad , J.-P. Vincensini , M. Iannetta , S.G. Parisi , L. Sarmati , K. Lacombe Tor Vergata University of Rome, Medicina dei Sistemi, Rome, Italy, Tor Vergata Policlinic, Rome, Italy, Hopital Saint Antoine, Paris, France, Università di Padova, Padova, Italy, Sorbonne Université, Paris, France General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: HBV anti-HBc antibody positivity (HBcAb+) may be a surrogate marker for hepatitis B occulta infection (OBI), but is not a contraindication to switch to two-drug therapy (2DR). Method: A European multicentre retrospective study was conducted to investigate the impact of HBcAb positivity in PLWH undergoing swtich to 2DR consisting of Lamivudine and Dolutegravir (3TC/DTG). A comparison analysis was conducted between HBcAb-positive and HBcAb-negative patients in terms of HIV-RNA suppression: (1): Target Not Detected (TND) <20 cp/ml; (2) Target Detected (TD) <20 cp/ml; and (3) Detectable >20 cp/ml <50 cp/ml Results: 267 patients on 2DR with 3TC-DTG were included. predominantly male (181, 67.8%), with a median age of 41 years (IQR 32-52). From cART initiation to swicth there was a recovery of CD4+ levels (306 [203-442] and 754 [562-961] respectively). 76 patients were found HBcAb-positive. HBcAb-positive patients were older than negatives (45 years [35-54]) and had a lower CD4+ nadir (248 vs 349 cells/mmc, p=0.007), whereas at the time of switch there was no significant difference in CD4+ between the two groups (767 vs 741, p=0.84). Subpopulations did not differ in maintainance of virological suppression at pre-switch timepoints (p=0.35 at 24 months pre-switch; p=030, at 12 months pre-switch and p=0.15 at the time of switch). Differently, at 12 months post-switch only 52 HBcAb-positive patients (69.3%) were TND, compared to 164 (85.4%) HBcAb-negative (p=0.004), as well as at 24 months (HBcAb-positive TND 50 [72.5%] and HBcAb-negative TND 143 [89.9%], p=0. 001) and at 36 months post-switch to 3TC-DTG (HBcAb-positive TND 30 [66.7%] and HBcAb-negative TND 90 [92.8%], p=0.001). Conclusions: In the 2DR switch with 3TC-DTG of PLWH experienced, HBcAb positivity should be considered as a criterion for simplification and possibly for closer monitoring of HIV-RNA and HBV-DNA and liver function indices General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1,2 2 2 3 3 1,2 4 1,2 3,5 1 2 3 4 5 170 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=